Truvada (Emtricitabine/tenofovir disoproxil fumarate tablets)


New combination: FDA approved the combination tablet of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (Truvada, Gilead Sciences) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 in adults at high-risk in combination with safer sex practices.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.